Literature DB >> 12197845

The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease.

M A van Herwaarden1, M Samsom, H Rydholm, A J P M Smout.   

Abstract

BACKGROUND: Baclofen decreases gastro-oesophageal reflux episodes in healthy subjects by reducing the incidence of transient lower oesophageal sphincter relaxations. AIM: To investigate the effect of baclofen on reflux symptoms, oesophageal pH and lower oesophageal sphincter manometry in patients with gastro-oesophageal reflux disease.
METHODS: A double-blind, placebo-controlled, two-way crossover design was used to study the effect of baclofen on heartburn and regurgitation 3 h after a provocation test meal in 37 patients with gastro-oesophageal reflux disease. Additionally, in 20 of these patients, the effect of baclofen on oesophageal pH, transient lower oesophageal sphincter relaxations and basal lower oesophageal sphincter pressure was studied.
RESULTS: Baclofen significantly decreased the acid reflux time and the incidence of gastro-oesophageal reflux episodes (8.3 +/- 8.8% vs. 12.4 +/- 12.0%, P = 0.03 and 10.9 +/- 7.3 per 3 h vs. 18.7 +/- 12.4 per 3 h). The incidence of transient lower oesophageal sphincter relaxations was significantly lower with baclofen than with placebo (15.1 +/- 6.4 per 3 h vs. 22.8 +/- 5.4 per 3 h, P < 0.0001). Lower oesophageal sphincter pressure and the percentage of transient lower oesophageal sphincter relaxations associated with reflux were not affected by baclofen. No significant effect on symptom scores was observed.
CONCLUSIONS: Baclofen decreases post-prandial acid reflux in patients with gastro-oesophageal reflux disease by reducing the incidence of transient lower oesophageal sphincter relaxations. No effect of a single dose of baclofen on reflux symptoms could be demonstrated in this 3-h post-prandial study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197845     DOI: 10.1046/j.1365-2036.2002.01325.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Potentiation of mouse vagal afferent mechanosensitivity by ionotropic and metabotropic glutamate receptors.

Authors:  James A Slattery; Amanda J Page; Camilla L Dorian; Stuart M Brierley; L Ashley Blackshaw
Journal:  J Physiol       Date:  2006-08-31       Impact factor: 5.182

Review 2.  Physiology of reflux disease: role of the lower esophageal sphincter.

Authors:  P F Crookes
Journal:  Surg Endosc       Date:  2006-03-23       Impact factor: 4.584

3.  Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile.

Authors:  M Kalinichev; T Donovan-Rodriguez; F Girard; E Riguet; M Rouillier; B Bournique; H Haddouk; V Mutel; S Poli
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

4.  A Randomized Double-Blind, Placebo-Controlled, Cross-Over Study Using Baclofen in the Treatment of Rumination Syndrome.

Authors:  Ans Pauwels; Charlotte Broers; Brecht Van Houtte; Nathalie Rommel; Tim Vanuytsel; Jan Tack
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

Review 5.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

Review 6.  Chronic Burping and Belching.

Authors:  M Zad; A J Bredenoord
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-23

7.  Beyond acid suppression: new pharmacologic approaches for treatment of GERD.

Authors:  Paul Kuo; Richard H Holloway
Journal:  Curr Gastroenterol Rep       Date:  2010-06

Review 8.  Medical Treatment of Gastroesophageal Reflux Disease.

Authors:  Daniel A Kroch; Ryan D Madanick
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 9.  Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?

Authors:  James Wise; Jeffrey L Conklin
Journal:  Curr Gastroenterol Rep       Date:  2004-06

10.  Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor.

Authors:  Mohammad Niazi; Stanko Skrtic; Magnus Ruth; Ann A Holmberg
Journal:  Drugs R D       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.